Emergent Biosolutions
EBS

$7.52

1.44%

Market Cap: $394M

About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Employees: 1,600

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

120% more capital invested

Capital invested by funds: $94.4M [Q1] → $207M (+$113M) [Q2]

71% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 28

17% more funds holding

Funds holding: 120 [Q1] → 140 (+20) [Q2]

3% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 36

13.3% less ownership

Funds ownership: 71.34% [Q1] → 58.04% (-13.3%) [Q2]

47% less call options, than puts

Call options by funds: $3.09M | Put options by funds: $5.83M

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

6%

upside

Avg. target

$9

20%

upside

High target

$16

113%

upside

8 analyst ratings

8 positive

100%

0 neutral

0%

0 negative

0%

Rodman & Renshaw	113%upside $16	Buy Initiated	22 Aug 2024
Benchmark Robert Wasserman 50% 1-year accuracy 22 / 44 met price target	6%upside $8	Buy Reiterated	16 Aug 2024
Benchmark Robert Wasserman 50% 1-year accuracy 22 / 44 met price target	6%upside $8	Buy Reiterated	9 Aug 2024
Benchmark Robert Wasserman 50% 1-year accuracy 22 / 44 met price target	6%upside $8	Buy Reiterated	3 Jul 2024
Benchmark Robert Wasserman 50% 1-year accuracy 22 / 44 met price target	6%upside $8	Buy Reiterated	2 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 17 articles about EBS published over the past 30 days

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company

CNBC Television

Upside for Emergent Bio if they can get Mpox vaccine rollout right, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk opportunities in pharma investing following approval of Emergent Bio's Mpox vaccine.

Upside for Emergent Bio if they can get Mpox vaccine rollout right, says Mizuho's Jared Holz

Zacks Investment Research

EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication

The FDA approves Emergent BioSolutions' sBLA seeking a label expansion of ACAM2000 for the mpox indication. Stock rises in pre-market trading.

EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication

Investors Business Daily

Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine

The FDA approved a supplemental application to expand Emergent BioSolutions' existing smallpox vaccine to include Mpox.

Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

GAITHERSBURG, Md., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced it is kicking off the second year of the Ready to Rescue initiative, which will include new college football tailgate stops, in-stadium activities, Greek Life events and student wellness clinics. As part of these expanded efforts, pro football legend and campaign spokesperson, Emmitt Smith, will continue to share his story to raise awareness of opioid risks and inspire students, parents, faculty and alumni to be prepared to save a life with NARCAN® Nasal Spray, which is available over-the-counter (OTC).

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection

Thursday, the FDA approved Emergent BioSolutions Inc.'s EBS supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection.

Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection

Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine

The FDA approves the company's smallpox vaccine for Mpox.

Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine

US FDA approves use of Emergent's smallpox vaccine for people at high risk of mpox

Emergent BioSolutions on Thursday said the U.S. Food and Drug Administration (FDA) had approved expanded use of its ACAM2000 smallpox vaccine to include people at high risk for mpox infection.

US FDA approves use of Emergent's smallpox vaccine for people at high risk of mpox

Emergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection. The approval is based on previously available human safety data and data from a well-controlled animal study in which ACAM2000® vaccine was shown to be effective in protecting against mpox virus exposure.

Emergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals

GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472). Emergent received approximately $30 million at closing, which is subject to customary post-closing adjustments.

Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals

See News Rankings